Literature DB >> 24980552

IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers.

Pierfrancesco Marra1, Sumi Mathew1, Anita Grigoriadis1, Yin Wu2, Fernanda Kyle-Cezar2, Johnathan Watkins1, Mamunur Rashid3, Emanuele De Rinaldis4, Sonya Hessey1, Patrycja Gazinska1, Adrian Hayday2, Andrew Tutt5.   

Abstract

Despite its aggressive nature, triple-negative breast cancer (TNBC) often exhibits leucocyte infiltrations that correlate with favorable prognosis. In this study, we offer an explanation for this apparent conundrum by defining TNBC cell subsets that overexpress the IL15 immune receptor IL15RA. This receptor usually forms a heterotrimer with the IL2 receptors IL2RB and IL2RG, which regulates the proliferation and differentiation of cytotoxic T cells and NK cells. However, unlike IL15RA, the IL2RB and IL2RG receptors are not upregulated in basal-like TNBC breast cancer cells that express IL15RA. Mechanistic investigations indicated that IL15RA signaling activated JAK1, STAT1, STAT2, AKT, PRAS40, and ERK1/2 in the absence of IL2RB and IL2RG, whereas neither STAT5 nor JAK2 were activated. RNAi-mediated attenuation of IL15RA established its role in cell growth, apoptosis, and migration, whereas expression of the IL15 cytokine in IL15RA-expressing cells stimulated an autocrine signaling cascade that promoted cell proliferation and migration and blocked apoptosis. Notably, coexpression of IL15RA and IL15 was also sufficient to activate peripheral blood mononuclear cells upon coculture in a paracrine signaling manner. Overall, our findings offer a mechanistic explanation for the paradoxical association of some high-grade breast tumors with better survival outcomes, due to engagement of the immune stroma. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24980552     DOI: 10.1158/0008-5472.CAN-14-0637

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  IL-2 and Beyond in Cancer Immunotherapy.

Authors:  John M Wrangle; Alicia Patterson; C Bryce Johnson; Daniel J Neitzke; Shikhar Mehrotra; Chadrick E Denlinger; Chrystal M Paulos; Zihai Li; David J Cole; Mark P Rubinstein
Journal:  J Interferon Cytokine Res       Date:  2018-02       Impact factor: 2.607

2.  Identification of a five-lncRNA signature for the diagnosis and prognosis of gastric cancer.

Authors:  Zhi-Yuan Fan; Wentao Liu; Chao Yan; Zheng-Lun Zhu; Wei Xu; Jian-Fang Li; Liping Su; Chen Li; Zheng-Gang Zhu; Bingya Liu; Min Yan
Journal:  Tumour Biol       Date:  2016-07-26

3.  IFNs Drive Development of Novel IL-15-Responsive Macrophages.

Authors:  Scott M Gordon; Mailyn A Nishiguchi; Julie M Chase; Sneha Mani; Monica A Mainigi; Edward M Behrens
Journal:  J Immunol       Date:  2020-07-20       Impact factor: 5.422

4.  Tumor cell-expressed IL-15Rα drives antagonistic effects on the progression and immune control of gastric cancer and is epigenetically regulated in EBV-positive gastric cancer.

Authors:  Jing Wei; Chen Guo; Xiang An; Wenxuan Miao; Chenli Zhang; Binsheng Wang; Wei Cai; Min Li; Fangfang Zhang
Journal:  Cell Oncol (Dordr)       Date:  2020-08-07       Impact factor: 6.730

5.  A pan-cancer modular regulatory network analysis to identify common and cancer-specific network components.

Authors:  Sara A Knaack; Alireza Fotuhi Siahpirani; Sushmita Roy
Journal:  Cancer Inform       Date:  2014-10-28

6.  Reciprocal regulation of the Il9 locus by counteracting activities of transcription factors IRF1 and IRF4.

Authors:  Lucia Campos Carrascosa; Matthias Klein; Yohko Kitagawa; Christina Lückel; Federico Marini; Anika König; Anna Guralnik; Hartmann Raifer; Stefanie Hagner-Benes; Diana Rädler; Andreas Böck; Cholho Kang; Michael Lohoff; Holger Garn; Bianca Schaub; Friederike Berberich-Siebelt; Shimon Sakaguchi; Tobias Bopp; Magdalena Huber
Journal:  Nat Commun       Date:  2017-05-12       Impact factor: 14.919

7.  Theranostic multimodular potential of zinc-doped ferrite-saturated metal-binding protein-loaded novel nanocapsules in cancers.

Authors:  Sishir K Kamalapuram; Rupinder K Kanwar; Kislay Roy; Rajneesh Chaudhary; Rakesh Sehgal; Jagat R Kanwar
Journal:  Int J Nanomedicine       Date:  2016-04-01

8.  Profile of the breast cancer susceptibility marker rs4245739 identifies a role for miRNAs.

Authors:  Sumadi Lukman Anwar; Wahyu Wulaningsih; Johnathan Watkins
Journal:  Cancer Biol Med       Date:  2017-11       Impact factor: 4.248

Review 9.  PRAS40 signaling in tumor.

Authors:  Dan Lv; Lianying Guo; Ting Zhang; Lin Huang
Journal:  Oncotarget       Date:  2017-04-20

10.  Smoking, second-hand smoke exposure and smoking cessation in relation to leukocyte telomere length and mortality.

Authors:  Wahyu Wulaningsih; Fidel Emmanuel C Serrano; Adi Utarini; Tetsuya Matsuguchi; Johnathan Watkins
Journal:  Oncotarget       Date:  2016-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.